TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2122007
Drug: Neoadjuvant methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant methotrexate, cisplatin and vinblastine chemotherapy plus 2 additional courses of cisplatin and 4,000 cGy irradiation.
Study: 2122007
Drug: Full chemotherapy
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full chemotherapy and radiotherapy (including a radiotherapy boost to a total of 6,480 cGy plus 1 additional course of cisplatin).
Study: 2122007
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with dose reductions due to stomatitis, bone marrow depression, and/or renal dysfunction.
Study: 2122007
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment efficacy and tolerability.
Study: 31563397
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg dexamethasone IV 24 hours after surgery
Study: 10753434
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (control group)
Study: 30206195
Drug: ACT-based stress
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-based stress management program (twice a week for four weeks)
Study: 24030238
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program (twice-weekly for 12 weeks, including muscle power training at 40-60% of one-repetition maximum, balance and gait retraining)
Study: 22565589
Drug: Weight based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight based, higher-dose (HD) enoxaparin 0.5 mg/kg QDay, n = 11
Study: 22565589
Drug: Weight based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight based, lower-dose (LD) enoxaparin 0.4 mg/kg QDay, n = 9
Study: 22565589
Drug: Fixed-dose (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose (FD) enoxaparin 40 mg daily, n = 11
Study: 11882226
Drug: Prilocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (3 mg/kg)
Study: 11882226
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg/kg)
Study: 9496204
Drug: Propofol-low-dose fentanyl-nitrous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-low-dose fentanyl-nitrous oxide-vecuronium, tracheal extubation immediately after surgery (group Ia)
Study: 10862645
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy without change (Group B)
Study: 8418174
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Chlamydia-positive NGU
Study: 8418174
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for gonorrhea
Study: 8418174
Drug: Chlamydia-positive NGU
Normalized name: Chlamydia trachomatis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia-positive NGU after cessation of therapy
Study: 25641591
Drug: Stretch-and-flow voice
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretch-and-flow voice therapy
Study: 19454032
Drug: Dexmedetomidine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.2 to 0.7 microg/kg/hr (with or without loading doses of 1 microg/kg)
Study: 16736128
Drug: Glucose concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose concentrations of 8.3 mmol/l
Study: 16736128
Drug: Glucose concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose concentrations of 11.1 mmol/l
Study: 16736128
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of insulin
Study: 10228257
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion
Study: 15001601
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL (80 mg), once-daily for 8 weeks
Study: 15001601
Drug: Placebo, once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once-daily for 8 weeks
Study: 3101484
Drug: Ten-day penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ten-day penicillin V potassium therapy (250 mg three times daily)
Study: 18091007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of print materials and pedometer (COM)
Study: 29935939
Drug: Acute ∆9‐THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute ∆9‐THC administration
Study: 26909743
Drug: Curcuminoids (294
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (294 mg per day as micelles)
Study: 23379240
Drug: Afala, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afala, 2 tablets 4 times a day for 6 months
Study: 18359717
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nebulized budesonide suspension plus salbutamol and ipratropium bromide twice daily for 5 days (Group A)
Study: 18359717
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus aminophylline injection once daily for 5 days (Group C)
Study: 9528844
Drug: Ifosfamide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (3 g m(‐2) x (2 or 3) days as a 1‐h bolus)
Study: 9528844
Drug: Ifosfamide (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (same total dose as continuous infusion)
Study: 2650643
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial therapy and skin grafting after spontaneous eschar separation
Study: 2650643
Drug: Early excision
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early excision and topical antimicrobial therapy
Study: 1159265
Drug: Diazepam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (12 mg daily for two weeks)
Study: 24861133
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg single oral dose) plus Cyclosporine (600 mg single oral dose)
Study: 22648712
Drug: [¹³C]Palmitate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: [¹³C]Palmitate and octanoate administered via gastrointestinal endoscopy
Study: 18221433
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release alpha-lipoic acid (CRLA) for 3 months
Study: 16318978
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dydrogesterone per day during the first trimester of pregnancy
Study: 9322808
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg/d)
Study: 29656442
Drug: Lenvatinib (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (24 mg/d on a 28-day cycle)
Study: 26756115
Drug: Insulin during
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin during euglycemic hyperinsulinemia
Study: 26756115
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and post-insulin clamp
Study: 15828852
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg famotidine (single dose, intravenous or oral)
Study: 15828852
Drug: 0.25 mg/kg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally (multiple doses)
Study: 15828852
Drug: 0.5 mg/kg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/dose intravenously or 1 mg/kg/dose orally (subsequent doses)
Study: 8625185
Drug: Pelvic intraarterial
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (50 mg/m2)
Study: 8625185
Drug: Pelvic intraarterial
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (75 mg/m2)
Study: 8625185
Drug: Pelvic intraarterial
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intraarterial chemotherapy (IAC) with cisplatin (75 mg/m2)
Study: 8625185
Drug: Pelvic intraarterial
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intraarterial chemotherapy (IAC)
Study: 1852090
Drug: Milrinone (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (24-hour infusion)
Study: 6154200
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 or 0.2 mg)
Study: 22945718
Drug: Laser +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser + Prompt L‐Pop
Study: 19058684
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop
Study: 22945718
Drug: Air abrasion
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air abrasion + Prompt L‐Pop
Study: 19576277
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Study: 19576277
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium nitrite (0.06 mmol NaNO(2)/mmol Hb)
Study: 19576277
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.625 mg
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.45 mg
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.3 mg
Study: 15453549
Drug: Ropinirole (0.25-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.25-4.0 mg per day)
Study: 11606148
Drug: Sustained-release sodium
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release sodium fluoride, calcium citrate, and cholecalciferol (SR-NaF group)
Study: 9613265
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol at 5 micrograms.ml‐1
Study: 9613265
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol at 6 micrograms.ml‐1
Study: 9613265
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol at 7 micrograms.ml‐1
Study: 9613265
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol at 8 micrograms.ml‐1
Study: 422738
Drug: Loading regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading regimen of 2600 mg ASA divided into two equal doses 4 hours apart
Study: 422738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 650 mg ASA every 4 hours for 48 hours
Study: 31961048
Drug: Branded cream
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded cream control
Study: 22781385
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg intravenously every 3 to 4 weeks (control)
Study: 22781385
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg intravenously every 12 weeks
Study: 15499601
Drug: Fluorouracil/leucovorin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil/leucovorin chemotherapy alone
Study: 11573600
Drug: Hyaluronidase 150
Normalized name: hyaluronidase 1500 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase 150 IU ml(‐1)
Study: 11573600
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine and 1% ropivacaine with hyaluronidase 150 IU ml(‐1)
Study: 9745061
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential compression device
Study: 10636525
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate
Study: 31542129
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco) with transdermal nicotine patch
Study: 24588277
Drug: Topical ointment
Normalized name: Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ointment (Aquaphor Original Emollient)
Study: 23164480
Drug: prednisolone 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 7.5mg once daily
Study: 23164480
Drug: prednisolone 30mg
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 30mg once daily
Study: 21107748
Drug: 3.0 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/l propofol (n = 64)
Study: 9438318
Drug: OAC (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (20 mg omeprazole, 750 mg amoxicillin, and 250 mg clarithromycin, twice daily for 10 days)
Study: 9438318
Drug: BTC (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTC (240 mg bismuth subcitrate, 750 mg oxytetracycline, and 250 mg clarithromycin, twice daily for 10 days)
Study: 8483424
Drug: 3 implants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 implants, each containing 12 mg oestradiol valerate (E2V)
Study: 8483424
Drug: 4 implants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implants, each containing 27 mg oestradiol benzoate (E2B)
Study: 3717960
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of THP, 5-Fluorouracil and cyclophosphamide (Group A)
Study: 21250568
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control with perlite whitening formulation
Study: 17943257
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of TNF inhibitors (etanercept, infliximab, adalimumab) plus methotrexate (MTX)
Study: 17943257
Drug: TNF-blocking agents
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-blocking agents (etanercept, adalimumab, infliximab)
Study: 8723581
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (100 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Study: 1517652
Drug: Oxygen 5
Normalized name: oxygen 5 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 5 L/min delivered by mask
Study: 1517652
Drug: Air 5
Normalized name: Singulair 5mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air 5 L/min delivered by mask
Study: 6367246
Drug: 0.20 mg
Normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg beta-methyl digoxin
Study: 25223378
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1 mg
Study: 22906144
Drug: Active acupuncture
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupuncture treatment
Study: 16547082
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose oral amoxicillin (45 mg/kg/day)
Study: 17430101
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody therapies targeting tumor and/or tumor micro-environment in combination with gemcitabine
Study: 17430101
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor)
Study: 18976320
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug (AED) monotherapy
Study: 12796517
Drug: Outpatient conversion
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient conversion to monotherapy
Study: 12796517
Drug: Presurgical conversion
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical conversion to monotherapy
Study: 10976984
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment for osteoporosis
Study: 8879780
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate in 5% dextrose (0.7 mg/[kg.d] for 14 days, then 1 mg/kg every other day for 28 days)
Study: 8879780
Drug: Intralipid/amphotericin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid/amphotericin B (1 mg/[kg.d] for 14 days, then 1.5 mg/kg every other day for 28 days)
Study: 6866306
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin prophylaxis (5000 I.U. s.c. every 8 hr)
Study: 24886027
Drug: Developmentally Adapted
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmentally Adapted Cognitive Processing Therapy (D-CPT)
Study: 21208780
Drug: Brazil nut
Normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nut consumption providing approximately 290 μg of Se a day for 8 weeks
Study: 21118280
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg
Study: 17645378
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 300 mg in a single dose per week for 2 weeks
Study: 17645378
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 300 mg
Study: 8355864
Drug: Clonidine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.125 mg intravenously after induction of anesthesia
Study: 8355864
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (control)
Study: 2452254
Drug: Isoprinosine 3
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprinosine 3 g/day
Study: 18649766
Drug: Alprostadil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (20 microg) and radix Salviae miliorrhazae (40 ml) intravenously once a day for 2 weeks
Study: 18649766
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 3 times a day for 2 weeks and radix Salviae miliorrhazae (dropping pill)
Study: 8958487
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 with basal infusion (group SC+)
Study: 8958487
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 without basal infusion (group SC)
Study: 8958487
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms mL‐1 with basal infusion (group S+)
Study: 8958487
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 micrograms mL‐1 without basal infusion (group S)
Study: 1558400
Drug: UFT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT treatment
Study: 3847417
Drug: Inpatient cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient cardiac patient education program consisting of five daily 1-hour classes
Study: 31945074
Drug: Monthly training
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly training interval
Study: 26631058
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3.36 g daily for 3 months)
Study: 12850618
Drug: Nerve stimulation
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulation therapy
Study: 1168110
Drug: Beef lung
Normalized name: BEEF LUNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef lung heparin